A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia
Completed · Phase 1 · NCT05865535
Conditions: Cachexia
At a glance
- Research payments reported, 2025
- $737,176
- U.S. investigators named
- 12
- Sites paid
- 14
- Planned or actual enrollment
- 24
About the trial
- Sponsor
- AVEO Pharmaceuticals, Inc.
- Tested
- AV-380 (biological)
- Dates
- Started 2023-06-13; completion 2026-09-25
- Results posted
- Not yet
This open label ascending dose study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AV-380 in cancer patients with Cachexia. AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
From ClinicalTrials.gov, last updated 2026-11-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Aveo Pharmaceuticals, Inc. reported $737,176 in research payments for this study in 2025 (335 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Eric M. Cheung, D.O. Hematology & Oncology · Lakewood, CA
- Afshin E. Gabayan, M.D. Hematology & Oncology · Beverly Hills, CA
- Tara E. Seery Hematology & Oncology · Irvine, CA
- Mohamedtaki A. Tejani, M.D. Medical Oncology · Orlando, FL
- Vipin Ramprasad Lohiya, M.D. Hematology & Oncology · Fayetteville, GA
- Ralph J. Hauke, MD Hematology & Oncology · Omaha, NE
- Richard M. Zuniga, MD Hematology & Oncology · Babylon, NY
- Jennifer E. Selfridge, M.D. Medical Oncology · Cleveland, OH
- Eric Roeland, MD Hospice & Palliative Medicine · Portland, OR
- Rajiv Agarwal Hematology & Oncology · Nashville, TN
- Saleha S. Sajid, MD Hematology & Oncology · Kingwood, TX
- Arvind Chaudhry, MD Hematology & Oncology · Spokane, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Clinical Research Advisors LLC $207,282
- Community Clinical Trials $155,602
- Adventhealth Orlando, FL $68,532
- Ohsu Hospital and Clinics, OR $64,299
- Hoag Memorial Hospital Presbyterian $53,800
- Piedmont Cancer Institute, PC $51,940
- Cancer Blood Research Center LLC $34,165
- Medical Oncology Associates, P.s. $24,663
- Oncology Hematology West PC $22,380
- North Shore Hematology-Oncology Associates, P.c. $19,090
- Vanderbilt University Medical Center, TN $16,642
- Uh Cleveland Medical Center, OH $9,700
- Piedmont Cancer Institute PC $9,010
- Vanderbilt Ingram Cancer Center $72
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.